MRCPI, CCST (UK), Director and Senior Interventional Cardiologist, Lead for TAVI and Advanced Device Therapy, Fortis Hospitals, Bannerghatta Road, Bangalore, India
Series overview · 9 articles
Detection and Management of Heart Failure
May 24, 2026
Dr. Rajpal Singh is Director and Senior Interventional Cardiologist and Lead for TAVI and Advanced Device Therapy at Fortis Hospitals, Bannerghatta Road, Bangalore. This guide is based on a live Jivo Masterclass where he set out, for doctors across Africa, the detection and management of heart failure end to end, referenced throughout to the 2021 ESC Heart Failure Guidelines and the 2023 ESC focused update.
The series covers why heart failure is a growing pandemic even as acute MI mortality falls, the ESC diagnostic algorithm built around natriuretic peptides, the four stages that let a clinician catch patients before symptoms even start, the four pillars of guideline-directed medical therapy that should be started together rather than one at a time, why sacubitril/valsartan has replaced ACE inhibitors as first-line therapy, the SGLT2 inhibitor class that now applies regardless of diabetes status, the drugs to actively avoid, and when to refer for ICD, CRT, LVAD or transplant.
It closes with Dr. Singh's own answers to the doctors who joined: why beta blockers make patients feel worse before they feel better, managing a heart failure patient with liver cirrhosis and ascites, and the genitourinary infection risk that comes with SGLT2 inhibitors.
This guide is based on a live Jivo Masterclass — Dr. Rajpal Singh taught doctors across Africa on May 24, 2026.
Watch the full recording, or read the guide above.
FROM THE LIVE Q&A
Dr. Ivan, Uganda
Why do beta blockers initially worsen symptoms before improving survival in heart failure?
Dr. Rajpal Singh
A failing heart relies on two compensatory mechanisms: increased heart rate and elevated blood pressure. A beta blocker reduces both, so cardiac output falls initially and the patient feels rough — but only for the first one to two weeks. After that, sustained reduction in neurohormonal activation reverses adverse cardiac remodelling and the patient improves steadily. Always counsel patients about this dip in advance and reassure them it will get better; a heart failure nurse is an excellent resource for this kind of communication.
Frequently Asked Questions
Can BNP be normal in acute heart failure, and how does BNP help distinguish cardiac from respiratory dyspnoea?▼
BNP and NT-proBNP are released in response to myocardial wall stress, so a normal BNP with a normal ECG makes acute heart failure very unlikely as the cause of a patient's breathlessness — the dyspnoea is most likely pulmonary or another non-cardiac cause. One nuance: in a patient presenting late, days after the onset of acute heart failure while partially compensating, BNP can occasionally read lower than expected, so very recent-onset context still matters.
How would you approach severe ascites in a patient with heart failure and liver cirrhosis, with oedema and normal blood pressure?▼
This is congestive cardiac failure — combined right and left heart failure — and the patient should ideally be hospitalised for close monitoring of renal function and electrolytes. For NYHA class 3 or 4 patients like this, we now routinely add acetazolamide alongside loop diuretics, which improves diuresis and speeds resolution of congestion as long as renal function isn't severely impaired. If blood pressure is low, low-dose renal-dose dopamine in addition to diuretics can help significantly, particularly with right heart failure and valvular dysfunction. Given the liver cirrhosis, use a higher dose of spironolactone, since it also acts on hepatic ascites, and monitor hepatorenal function closely.
What is the risk of recurrent UTI with SGLT2 inhibitors?▼
The mechanism is glycosuria, which is a nidus for genitourinary infections — balanitis in men and UTIs in women, at an incidence of around 5 to 6%. Counsel every patient on personal and perineal hygiene when starting the drug. If a genitourinary infection develops, get a urine culture, and if confirmed, hold the SGLT2 inhibitor until it resolves, then restart with reinforced hygiene counselling.
What is the role of dobutamine in acute heart failure?▼
There is no substantial long-term beneficial role — it is like flogging a dead horse, a transient cardiac output boost without sustained benefit. It's useful only as a short-term emergency bridge for a profoundly hypotensive patient. We now more routinely use noradrenaline rather than dobutamine in acute low-output heart failure.
When should the Sgarbossa criteria not be used?▼
The Sgarbossa criteria identify acute myocardial infarction in the presence of a left bundle branch block, where it is otherwise difficult to tell whether ECG changes represent an acute MI or simply the LBBB pattern — specifically, 4mm or more of ST elevation discordant to the QRS is considered an acute MI regardless of the LBBB. This is used specifically in the context of chest pain with LBBB, not in the context of established heart failure management.
What guidelines underpin this heart failure series?▼
The 2021 ESC Heart Failure Guidelines and the 2023 ESC focused update, referenced throughout by Dr. Rajpal Singh in the masterclass this guide is drawn from.
What is Dr. Rajpal Singh's role and specialty?▼
He is Director and Senior Interventional Cardiologist and Lead for TAVI and Advanced Device Therapy at Fortis Hospitals, Bannerghatta Road, Bangalore.
What does this heart failure series cover from start to finish?▼
It runs from why heart failure is a growing pandemic even as acute MI mortality falls, through the ESC diagnostic algorithm, the four stages that allow early detection, the four pillars of therapy started together, the shift to sacubitril/valsartan as first-line, the SGLT2 inhibitor class, drugs to avoid, and the referral criteria for ICD, CRT, LVAD and transplant.
In This Series: Detection and Management of Heart Failure: What's to be Done and When to Refer
- 1.Detection and Management of Heart Failure
- 2.Diagnosing Heart Failure: Why Natriuretic Peptides Come Before the Echo
- 3.The Four Stages of Heart Failure: Catching Patients Before Symptoms Start
- 4.The Four Pillars of Heart Failure Therapy: Starting All Four at Once
- 5.Sacubitril/Valsartan: Why ARNI Has Replaced ACE Inhibitors as First-Line Therapy
- 6.SGLT2 Inhibitors in Heart Failure: A Class 1A Drug Regardless of Diabetes Status
- 7.Drugs to Avoid in Heart Failure: Calcium Channel Blockers, NSAIDs and DPP-4 Inhibitors
- 8.When to Refer for ICD, CRT, LVAD or Transplant in Advanced Heart Failure
- 9.Building a Heart Failure Clinic: The Model That Standardises Care